International Stem Cell (ISCO) Net Cash Flow (2010 - 2025)
International Stem Cell (ISCO) posted quarterly Net Cash Flow of $27000.0 for Q4 2025, up 135.06% year-over-year from $11486.2 in Q4 2024, and down 41.3% quarter-over-quarter from $46000.0 in Q3 2025.
International Stem Cell (ISCO) Net Cash Flow (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Net Cash Flow for 16 consecutive years, with $27000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow rose 135.06% year-over-year to $27000.0; the TTM figure through Dec 2025 stood at -$37000.0 (up 76.58% YoY), while the FY2025 annual figure was -$237000.0, up 33.8% from the prior year.
- Net Cash Flow fell to $27000.0 in Q4 2025 per ISCO's latest filing, from $46000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $439000.0 in Q2 2023 and bottomed at -$367000.0 in Q2 2021.
- Historically, Net Cash Flow has averaged $35400.0 across 5 years, with a median of $62000.0 in 2022.
- Annual changes were most pronounced in 2021 — Net Cash Flow sank 680.85% — and 2024, when it surged 352.08%.
- International Stem Cell's Net Cash Flow stood at -$334000.0 in 2021, then surged by 122.75% to $76000.0 in 2022, then soared by 107.89% to $158000.0 in 2023, then sank by 148.73% to -$77000.0 in 2024, then soared by 135.06% to $27000.0 in 2025.
- Business Quant data shows ISCO's Net Cash Flow at $27000.0 in Q4 2025, $46000.0 in Q3 2025, and -$332000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 225.59 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | -332,000.00 |
| Jun 30, 2025 | -332,000.00 |
| Mar 31, 2025 | 222,000.00 |
| Mar 31, 2025 | 222,000.00 |
| Dec 31, 2024 | -77,000.00 |
| Dec 31, 2024 | -77,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2024 | -96,000.00 |
| Jun 30, 2024 | -96,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Dec 31, 2023 | 158,000.00 |
| Dec 31, 2023 | 158,000.00 |
| Sep 30, 2023 | 48,000.00 |
| Sep 30, 2023 | 48,000.00 |